Zymeworks (NYSE:ZYME) initiated with Buy rating and $45 (73% upside) price target at Stifel.
Orchard Therapeutics (NASDAQ:ORTX) initiated with Outperform rating and $26 (81% upside) price target at Oppenheimer.
Tabula Rasa Healthcare (NASDAQ:TRHC) upgraded to Buy with a $75 (30% upside) price target at Stifel citing valuation, adding that its enhanced medication therapy management solution is “at least as good” as other large competitors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.